dizocilpine has been researched along with butaclamol in 3 studies
| Studies (dizocilpine) | Trials (dizocilpine) | Recent Studies (post-2010) (dizocilpine) | Studies (butaclamol) | Trials (butaclamol) | Recent Studies (post-2010) (butaclamol) |
|---|---|---|---|---|---|
| 77 | 0 | 30 | 45 | 0 | 16 |
| 77 | 0 | 30 | 33 | 0 | 8 |
| Protein | Taxonomy | dizocilpine (IC50) | butaclamol (IC50) |
|---|---|---|---|
| D(2) dopamine receptor | Homo sapiens (human) | 0.0123 | |
| D | Rattus norvegicus (Norway rat) | 0.0053 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0053 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.05 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0053 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0053 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0139 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0053 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.05 | |
| D(1B) dopamine receptor | Homo sapiens (human) | 0.05 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0525 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E | 1 |
| Bartoccini, F; Carminati, P; Castorina, M; Di Cesare, MA; Di Serio, S; Gallo, G; Ghirardi, O; Giorgi, F; Giorgi, L; Minetti, P; Piersanti, G; Tarzia, G; Tinti, MO | 1 |
| Altenbach, RJ; Brioni, JD; Carr, TL; Chandran, P; Cowart, MD; Esbenshade, TA; Honore, P; Hsieh, GC; Lewis, LG; Liu, H; Manelli, AM; Marsh, KC; Milicic, I; Miller, TR; Strakhova, MI; Vortherms, TA; Wakefield, BD; Wetter, JM; Witte, DG | 1 |
3 other study(ies) available for dizocilpine and butaclamol
| Article | Year |
|---|---|
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Male; Mice; Microsomes, Liver; Molecular Structure; Pilocarpine | 2016 |
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Cell Line; Cricetinae; Cricetulus; Drug Design; Humans; Imidazoles; Male; Models, Molecular; Motor Activity; Purines; Radioligand Assay; Rats; Rats, Inbred F344; Structure-Activity Relationship; Triazoles | 2005 |
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperalgesia; Ligands; Mice; Molecular Structure; Pain; Peritonitis; Quinazolines; Rats; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Stereoisomerism; Structure-Activity Relationship | 2008 |